SCHEMBL6417812

SCHEMBL6417812

COCCN(CCCN)CCOC

nearest known ligand 0.45

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.33
PIK3CD O00329 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
DDAH1 O94760 1/20 0.32
LCK P06239 1/20 0.32
ODC1 P11926 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32679310 0.90 CHRM2 (0.33) CHRM2DDAH1LCKODC1
SCHEMBL14075564 0.90 CHRM2 (0.33) CHRM2DDAH1LCKODC1
SCHEMBL10820636 0.89 DDAH1 (0.32) DDAH1
SCHEMBL31614498 0.87 CA2 (0.33)
SCHEMBL24899453 0.87 CA2 (0.33)
SCHEMBL8309353 0.84 PIK3CD (0.36) PIK3CDMEN1KMT2ALCK
Hydrochloric Acid SCHEMBL27224865 0.82 PIK3CD (0.34) PIK3CDMEN1KMT2ALCK
SCHEMBL20036528 0.82 TDP1 (0.39) MEN1KMT2ADDAH1
SCHEMBL13925694 0.81 PIK3CD (0.37) PIK3CDMEN1KMT2A
SCHEMBL1292539 0.81 PIK3CD (0.43) PIK3CDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118556115-A Surface treatment agent, material to be treated having coating film, and method for producing same 日本帕卡濑精株式会社 2024-08-27 CN disclosed
WO-2023071601-A1 DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 天津市昕晨投资发展有限公司 2023-05-04 WO disclosed
CN-111936558-B Polysiloxane compounds and compositions 日本帕卡濑精株式会社 2022-03-18 CN disclosed
EP-1450774-A4 CHLORIN PHOTOSENSITIZING AGENTS FOR USE IN PHOTODYNAMIC THERAPY MIRAVANT PHARM INC (US) 2005-10-26 EP disclosed
US-20050020559-A1 Chlorin photosensitizing agents for use in photodynamic therapy MIRAVANT PHARMACEUTICALS, INC., 2005-01-27 US disclosed
EP-1450774-A2 CHLORIN PHOTOSENSITIZING AGENTS FOR USE IN PHOTODYNAMIC THERAPY Miravant Pharmaceuticals, Inc. (US) 2004-09-01 EP disclosed
WO-2003028629-A2 CHLORIN PHOTOSENSITIZING AGENTS FOR USE IN PHOTODYNAMIC THERAPY MIRAVANT PHARMACEUTICALS, INC. (US) 2003-04-10 WO disclosed
EP-0790986-B1 ANILINE DERIVATIVES ZENECA LTD (GB) 1999-01-20 EP disclosed
EP-0790986-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1997-08-27 EP disclosed
WO-1996015118-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1996-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020559-A1 Chlorin photosensitizing agents for use in photodynamic therapy VHL, CRY1, PHLPP1 CHRM2 4286/4885PIK3CD 653/4885MEN1 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.